Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Luigi Roffi, Savino Bruno(Humanitas University), Pierpaolo Parravicini(Azienda Socio Sanitaria Territoriale della Valtellina e Alto Lario), Chiara Corradi(University of Pisa), Roberto Ceriani(Paoli Hospital), Valentina Bellia, Pietro Pioltelli(University of Milan), Giovanni Fornaciari, Massimo Pozzpi, Paoolo Del Poggio, Angelo Rossini(Centro Universitário Barão de Mauá), Guido Colloredo(King's College Hospital), G Ramella, G. Bellati(Fondazione Ricerca Molinette)
PubMed
January 1, 2008
Cited by 41
Related Papers
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways
|Nature Communications|2015|312
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
|Journal of Hepatology|2016|273
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
|Journal of Hepatology|2022|172